Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy

J Antimicrob Chemother. 2017 Oct 1;72(10):2955-2958. doi: 10.1093/jac/dkx222.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use*
  • Coinfection / blood
  • Coinfection / complications
  • Coinfection / drug therapy
  • Drug Therapy, Combination
  • Female
  • Fluorenes / therapeutic use*
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Middle Aged
  • Porphyria Cutanea Tarda / blood
  • Porphyria Cutanea Tarda / diagnosis
  • Porphyria Cutanea Tarda / drug therapy*
  • Porphyria Cutanea Tarda / etiology
  • Sofosbuvir
  • Uridine Monophosphate / analogs & derivatives*
  • Uridine Monophosphate / therapeutic use

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Fluorenes
  • ledipasvir, sofosbuvir drug combination
  • Uridine Monophosphate
  • Sofosbuvir